実臨床での関節リウマチに用いる生物製剤および分子標的合成抗リウマチ薬の安全性: ARTIS プログラムからのデータ
Ann Rheum Dis. 2023;82(5):601–610 doi: 10.1136/ard-2022-223762
Nationwide register-based cohort study corroborates and extends previous evidence that the currently available biologic/targeted synthetic DMARDs have an acceptable and, on the whole, similar safety profile.
Frisell, et al. provide a comprehensive assessment of safety outcomes of particular interest, for most biologic/targeted synthetic DMARDs available for the treatment of RA. They highlight some differences concerning tolerability, specific infection risks, and certain serious, but rare, outcomes, and conclude that these data should be combined with corresponding data on effectiveness to inform risk-benefit trade-offs.
